Fig. 1.

The proposed treat-and-plan (TAP) regimen for the treatment of nAMD during the COVID-19 pandemic. New patients are assessed during a baseline visit and receive a loading dose of three monthly intravitreal injections. The monthly injections are performed according to the in-and-out injection visit model. A regular assessment and treatment plan visit is held 4 weeks after the last injection. During this visit, disease activity is assessed and the patient is allocated to a fixed-interval regimen accordingly. The first injection of this fixed-interval regimen (3 × q6 weeks or 3 × q4 weeks) is carried out during the same visit. The subsequent injections are performed according to the in-and-out injection visit model. The interval between last injection of the previous fixed-interval regimen and the next assessment visit is equal to the previously set interval. During subsequent assessment visits, the patient is allocated to one of the fixed-interval regimens based on disease activity and receives the first injection of the next fixed-interval regimen. *Disease activity is defined as follows: exudative signs on OCT (intraretinal or subretinal fluid) or on fundus examination (new macular hemorrhage). ^†2 × q10 weeks and 2 × q12 weeks are possible fixed-interval regimens for subsequent assessment visits. VA visual acuity, OCT optical coherence tomography, DFE dilated fundus examination